Our latest news on Magmaris RMS

15
November
2020
| 17:56 Europe/Amsterdam

Future of Resorbable Scaffolds Looks Rosier

As more data comes in, there’s plenty of reasons to be optimistic about scaffolds

In their short time on the market, bioresorbable vascular scaffolds have generated plenty of discussion within interventional cardiology. According to the authors of “Fading Away or Hope for the
30
September
2019
| 00:00 Europe/Amsterdam

TCT 2019: Real-World Registry Data Confirm Safety of Resorbable Scaffold Technology

Magmaris Scaffold Shows Low Complication Rates, Benefiting Patients with Both Stable and Unstable Coronary Artery Disease

Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery
07
June
2019
| 00:00 Europe/Amsterdam

EuroPCR 2019: New Data Confirms Future of Resorbable Magnesium Scaffolds

Registries Show Magmaris’ Safety While Development Insights Offer Promising Prospects for Magnesium-Based Scaffolds

New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior
05
March
2019
| 00:00 Europe/Amsterdam

Early Resorption, Low Complications: Late Breaker at CRT 2019 Shows Safety and Efficacy of Magmaris

New BIOSOLVE-IV One-Year Data Underline the Benefit of the Resorbable Magnesium Scaffold for Patients with De Novo Coronary Artery Lesions

Preliminary data from the BIOSOLVE-IV registry strengthen the clinical evidence in favor of BIOTRONIK’s resorbable magnesium scaffold Magmaris for de novo coronary artery lesions. Presented as
24
September
2018
| 00:00 Europe/Amsterdam

TCT 2018: Magmaris Resorbable Magnesium Scaffold Demonstrates Early Endothelialization and Reduced Rates of Late Scaffold Thrombosis

Data from Multiple Clinical Studies Provide New Insight into the Clinical Benefits of Resorbable Magnesium Scaffolds

Preliminary data from BIOSOLVE-IV registry shows low target lesion failure (TLF) rates of 4.3% with Magmaris and only one case of scaffold thrombosis (after DAPT interruption before the
14
June
2018
| 00:00 Europe/Amsterdam

BIOTRONIK Successfully Concludes Magmaris 2,000 Program at Two Years Since CE Mark

Based on More Than 2,000 Implanted Scaffolds, 96% of Physicians Rate the Leading Magnesium-Based Resorbable Scaffold as Good or Very Good

Ever since its CE launch in June 2016, BIOTRONIK’s Magmaris has been implanted by more than 650 physicians in over 350 hospitals across 45 countries. As part of its Magnesium 2,000 program, a